ipilimumab,nivolumab
bms
['sclc', 'lcsm,(-blcsm)', '/ipi', 'nivo', 'ipi/', '9la', 'nsclc']
dr presents poster with 3year update for checkmate 9la comparing first line nivo/ipi/chemo regimen vs chemo. patients in treatment cohort continued overall survival benefit (27% vs 19% on chemo alone) regardless of histology or pdl1 expression. #lcsm #nsclc #asco22 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.